Skip to main content
G

GapScore

GapScore provides a biotech diagnostic platform that detects single‑stranded DNA replication gaps in cancer cells, uncovering hidden vulnerabilities in tumor DNA replication. By quantifying these defects, the platform offers a novel biomarker that predicts how tumors will respond to specific therapies, enabling researchers and clinicians to tailor treatment plans to each patient’s tumor profile. This approach aims to improve therapeutic effectiveness while reducing unnecessary toxicity.

Updated 13 days ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Current cancer diagnostics often focus on genetic mutations and protein expression, overlooking functional defects in DNA replication that can influence treatment response. Without tools to detect these replication gaps, clinicians may select therapies that are less effective and expose patients to unnecessary toxicity.

Solution

GapScore offers a biotech diagnostic platform that quantifies single‑stranded DNA replication gaps in tumor cells, providing a functional biomarker of DNA integrity. By measuring these previously unrecognized defects, the platform predicts how a specific tumor is likely to respond to targeted therapies and DNA‑damage agents. The assay integrates with standard pathology workflows, delivering results that can be interpreted alongside existing molecular data. Researchers can use the data to stratify pre‑clinical models, while clinicians can tailor treatment regimens to each patient’s replication‑gap profile, aiming to improve efficacy and reduce adverse effects.

Target Audience

Primary users are oncology researchers developing targeted therapies and clinical oncologists seeking functional biomarkers to personalize cancer treatment plans.

Features

  • Sensitive detection of single‑stranded DNA replication gaps using proprietary assay technology
  • Quantitative readout that correlates gap burden with predicted therapeutic response
  • Compatibility with routine biopsy samples and standard histology processing
  • Integrated data reporting that aligns with existing molecular diagnostic results
  • Scalable workflow suitable for both research laboratories and clinical diagnostic labs
This profile is AI-generated and may contain inaccuracies.